ECO ANIMAL HEALTH GROUP PLC Logo

ECO ANIMAL HEALTH GROUP PLC

Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.

EAH | IL

Overview

Corporate Details

ISIN(s):
GB0005056469 (+2 more)
LEI:
2138009XN9DJ3YP7OB55
Country:
United Kingdom
Address:
THE GRANGE, 100 HIGH STREET, N14 6BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ECO Animal Health Group PLC is a global animal health biotechnology company specializing in the research, development, registration, and marketing of pharmaceutical and biological products. The company focuses on providing innovative solutions for economically important respiratory and enteric diseases, primarily targeting the swine and poultry markets. Its flagship product is Aivlosin® (marketed as Valosin® in some regions), a therapeutic used to improve animal health and performance, contributing to the global food supply chain. Committed to pioneering R&D, ECO Animal Health continually works on developing new products and enhancing its existing brands. The company operates through a global network of partnerships and distributors, maintaining a presence in over 70 countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 08:00
Board/Management Information
Head of Global R&D
English 12.1 KB
2025-08-21 13:29
Post-Annual General Meeting Information
Result of General Meeting
English 12.4 KB
2025-08-13 08:00
Share Issue/Capital Change
Block Listing Return
English 17.8 KB
2025-08-06 18:09
Major Shareholding Notification
Holding(s) in Company
English 25.3 KB
2025-07-17 08:00
Major Shareholding Notification
Holding(s) in Company
English 40.5 KB
2025-07-15 14:00
Director's Dealing
Director/PDMR Shareholding
English 22.8 KB
2025-07-14 08:00
Earnings Release
Results for the year ended 31 March 2025
English 1.2 MB
2025-07-08 17:10
Pre-Annual General Meeting Information
Notice of General Meeting and Notice of Results
English 15.3 KB
2025-03-13 08:00
Regulatory News Service
R&D Day
English 11.7 KB
2025-03-03 08:00
Regulatory News Service
Submission of Marketing Authorisation Application
English 13.9 KB
2025-02-24 17:08
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-02-19 08:00
M&A Activity
Disposal of non-core assets
English 11.4 KB
2025-02-18 08:00
Remuneration Information
Block listing Interim Review
English 14.9 KB
2025-02-13 08:00
Report Publication Announcement
Notice of R&D Day
English 10.2 KB
2024-12-20 08:00
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all ECO ANIMAL HEALTH GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ECO ANIMAL HEALTH GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.